Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Chronic Hepatitis B Virus Epidemiology Forecast

DelveInsight’s ‘Chronic Hepatitis B Virus (CHB) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted CHB epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Chronic Hepatitis B Virus (CHB) Understanding

Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus that attacks and injures the liver. Millions of people are living with a chronic hepatitis B infection all around the world. The hepatitis B virus (HBV) is transmitted through blood and infected bodily fluids. It can be passed to others through direct contact with blood, unprotected sex, and use of illegal drugs, unsterilized or contaminated needles. Children with hepatitis B are more likely to contract it through:

  • Being born to a mother who has hepatitis B
  • Living in the same house with someone who is infected with hepatitis B, and sharing items such as toothbrushes or razorblades
  • Receiving multiple transfusions of blood or blood products
  • Being bitten so that the skin is broken by someone whose saliva contains the hepatitis B virus
  • Being a hemodialysis patient

 

HBV is most commonly spread through sexual contact, accounting for nearly two-thirds of acute HBV cases. It is considered as a “silent epidemic” because most people do not have symptoms when they are newly infected or chronically infected. Thus, they can unknowingly spread the virus to others and continue the silent spread of hepatitis B. Most hepatitis B infections clear up within 1–2 months without treatment. When the infection lasts more than 6 months, it can develop into chronic hepatitis B, which can lead to chronic inflammation of the liver, cirrhosis (scarring of the liver), liver cancer, and/or liver failure. HBV infection has been identified as an important cause of chronic hepatitis (35.9%) and liver cirrhosis (44.2%).

 

The symptoms of hepatitis B include fatigue, poor appetite, stomach pain, fever, nausea, vomiting, and occasionally joint pain, hives, or rash. Urine may become darker in color, and then jaundice (yellowing of the skin and whites of the eyes) may appear. Adults are more likely than children to develop symptoms; however, up to 50% of adults who have acute infection do not have any symptoms. The symptoms may appear within 6 weeks to 6 months after exposure, but usually 4 months. The virus can be found in blood and other body fluids several weeks before symptoms appear and generally persists for several months afterward.

Epidemiology Perspective by DelveInsight

The Chronic Hepatitis B Virus epidemiology division provides the insights about historical and current Chronic Hepatitis B Virus patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

In 2020, the overall prevalent cases of CHB accessed to be around 5,858,038 in the 7MM, which are expected to grow during the forecast period, i.e., 2021–2030.

 

The disease epidemiology covered in the report provides historical as well as forecasted  Chronic Hepatitis B Virus epidemiology segmented as [Total Prevalent cases of CHB, Total Diagnosed Prevalent cases of  CHB, Gender-Specific Cases of CHB, Age-Specific Cases of CHB, CHB cases by Impact on Liver (i.e., decompensated and compensated), and Total treated cases of CHB] in the 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

Country Wise- Chronic Hepatitis B Virus Epidemiology

Key Findings

  • Among the 7MM, the United States accounted for nearly 40% of the total prevalent population of CHB in the year 2020.
  • In EU-5 countries the highest number of diagnosed cases of CHB were in Germany, followed by Italy.
  • As per the secondary findings, overall CHB Virus affects more males than females. In addition, around half of the CHB cases are reported in the people age group of 44 years and below. In the 7MM, the age-specific diagnosed prevalent cases of CHB were 60,561, 519,638, 479,929, 510,925, 366,771, and 93,968 cases for the age group less than 18 years, 18–34 years, 35–44 years, 45–54 years, 55–64 years, and ≥65 years, in 2020.

Scope of the Report

  • The CHB report covers a detailed overview explaining its causes, symptoms, and pathophysiology, diagnosis, and treatment patterns.
  • The CHB Report and Model provide an overview of the risk factors and global trends of CHB in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
  • The report provides insight about the historical and forecasted patient pool of CHB in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of CHB.
  • The report provides the segmentation of the CHB epidemiology by total prevalent cases in the 7MM.
  • The report provides the segmentation of the CHB epidemiology by diagnosed prevalent cases in the 7MM.
  • The report provides the segmentation of the CHB epidemiology by age-specific diagnosed prevalent cases in the 7MM.
  • The report provides the segmentation of the CHB epidemiology by gender-specific diagnosed prevalent cases of CHB in the 7MM.
  • The report provides the segmentation of the CHB epidemiology by Impact on Liver (i.e. decompensated and compensated) diagnosed prevalent cases of CHB in the 7MM.
  • The report provides the segmentation of the CHB epidemiology by treated cases of CHB in the 7MM.

Report Highlights

  • 10-Year Forecast of CHB epidemiology
  • 7MM Coverage
  • Epidemiology Segmentation

KOL-Views

We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over CHB scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CHB?
  • What are the key findings pertaining to the CHB epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
  • What would be the total number of patients of CHB across the 7MM during the study period (2017–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of CHB ?

Reasons to buy

The CHB Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global CHB market
  • Quantify patient populations in the global CHB market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for CHB therapeutics in each of the markets covered
  • Understand the magnitude of CHB population by its severity
  • The CHB epidemiology report and model were written and developed by Masters and PhD CHB  level epidemiologists
  • The CHB Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Executive Summary of Chronic Hepatitis B Virus

3.1. Key Events

4. Epidemiology Forecast Flow

5. Background and Overview

5.1. Introduction

5.1.1. Acute and Chronic Hepatitis B Infection

5.1.2. Signs and Symptoms

5.1.3. Risk Factors and Causes

5.1.4. Transmission of Hepatitis B Virus

5.1.5. Pathophysiology

5.1.6. Stages of HBV Infection

5.1.7. Complications of Hepatitis B Virus Infection

5.2. Diagnosis of Hepatitis B Infection

5.2.1. Screening Tests for Hepatitis B Infection

5.2.2. Liver Related Blood Tests

5.2.3. Tests to Diagnose Hepatitis B Virus

5.2.4. Liver Biopsy for Hepatitis B Virus

5.2.5. Diagnostic Guidelines of Hepatitis B Infection

5.2.6. Prevention of Hepatitis B Infection

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Assumptions and Rationale

6.3. Epidemiology Scenario: 7MM

6.3.1. Total Prevalent Cases of CHB in the 7MM

6.3.2. Total Diagnosed Prevalent cases of CHB in the 7MM

6.3.3. Gender-specific Diagnosed Prevalent Cases of CHB in the 7MM

6.3.4. Age-specific Diagnosed Prevalent Cases of CHB in the 7MM

6.3.5. Diagnosed Prevalent Cases of CHB by Impact on Liver in the 7MM

6.3.6. Treated cases of CHB in the 7MM

7. The United States Epidemiology

7.1. Total Prevalent Cases of CHB in the United States

7.2. Total Diagnosed Prevalent cases of CHB in the United States

7.3. Gender-specific Diagnosed Prevalent Cases of CHB in the United States

7.4. Age-specific Diagnosed Prevalent Cases of CHB in the United States

7.5. Diagnosed Prevalent Cases of CHB by Impact on Liver in the United States

7.6. Treated cases of CHB in the United States

8. EU-5 Epidemiology

8.1. Germany

8.1.1. Total Prevalent Cases of CHB in Germany

8.1.2. Total Diagnosed Prevalent cases of CHB in Germany

8.1.3. Gender-specific Diagnosed Prevalent Cases of CHB in Germany

8.1.4. Age-specific Diagnosed Prevalent Cases of CHB in Germany

8.1.5. Diagnosed Prevalent Cases of CHB by Impact on Liver in Germany

8.1.6. Treated cases of CHB in Germany

8.2. France

8.2.1. Total Prevalent Cases of CHB in France

8.2.2. Total Diagnosed Prevalent cases of CHB in France

8.2.3. Gender-specific Diagnosed Prevalent Cases of CHB in France

8.2.4. Age-specific Diagnosed Prevalent Cases of CHB in France

8.2.5. Diagnosed Prevalent Cases of CHB by Impact on Liver in France

8.2.6. Treated cases of CHB in France

8.3. Italy

8.3.1. Total Prevalent Cases of CHB in Italy

8.3.2. Total Diagnosed Prevalent cases of CHB in Italy

8.3.3. Gender-specific Diagnosed Prevalent Cases of CHB in Italy

8.3.4. Age-specific Diagnosed Prevalent Cases of CHB in Italy

8.3.5. Diagnosed Prevalent Cases of CHB by Impact on Liver in Italy

8.3.6. Treated cases of CHB in Italy

8.4. Spain

8.4.1. Total Prevalent Cases of CHB in Spain

8.4.2. Total Diagnosed Prevalent cases of CHB in Spain

8.4.3. Gender-specific Diagnosed Prevalent Cases of CHB in Spain

8.4.4. Age-specific Diagnosed Prevalent Cases of CHB in Spain

8.4.5. Diagnosed Prevalent Cases of CHB by Impact on Liver in Spain

8.4.6. Treated cases of CHB in Spain

8.5. The United Kingdom

8.5.1. Total Prevalent Cases of CHB in the United Kingdom

8.5.2. Total Diagnosed Prevalent cases of CHB in the United Kingdom

8.5.3. Gender-specific Diagnosed Prevalent Cases of CHB in the United Kingdom

8.5.4. Age-specific Diagnosed Prevalent Cases of CHB in the United Kingdom

8.5.5. Diagnosed Prevalent Cases of CHB by Impact on Liver in the United Kingdom

8.5.6. Treated cases of CHB in the United Kingdom

9. Japan Epidemiology

9.1.1. Total Prevalent Cases of CHB in Japan

9.1.2. Total Diagnosed Prevalent cases of CHB in Japan

9.1.3. Gender-specific Diagnosed Prevalent Cases of CHB in Japan

9.1.4. Age-specific Diagnosed Prevalent Cases of CHB in Japan

9.1.5. Diagnosed Prevalent Cases of CHB by Impact on Liver in Japan

9.1.6. Treated cases of CHB in Japan

10. Appendix

10.1. Bibliography

10.2. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

List of Table

Table 1: Summary of CHB Epidemiology, and Key Events (2017–2030)

Table 2: Signs and Symptoms of Acute and Chronic Hepatitis B Infection

Table 3: Phases of Chronic Hepatitis B Infection

Table 4: Interpretation of Results

Table 5: Total Prevalent Cases of CHB in the 7MM, in Thousands (2017–2030)

Table 6: Total Diagnosed Prevalent cases of CHB in the 7MM, in Thousands (2017–2030)

Table 7: Gender-specific Diagnosed Prevalent Cases of CHB in the 7MM, in Thousands (2017–2030)

Table 8: Age-specific Prevalent Cases of CHB in the 7MM, in Thousands (2017–2030)

Table 9: Diagnosed Prevalent Cases of CHB by Impact on Liver in the 7MM, in thousands (2017–2030)

Table 10: Total Treated cases of CHB in the 7MM, in Thousands (2017–2030)

Table 11: Total Prevalent Cases of CHB in the United States, in Thousands (2017–2030)

Table 12: Total Diagnosed Prevalent cases of CHB in the United States, in Thousands (2017–2030)

Table 13: Gender-specific Diagnosed Prevalent Cases of CHB in the United States (2017–2030)

Table 14: Age-specific Prevalent Cases of CHB in the United States (2017–2030)

Table 15: Diagnosed Prevalent Cases of CHB by Impact on Liver in the United States (2017–2030)

Table 16: Total Treated cases of CHB in the United States (2017–2030)

Table 17: Total Prevalent Cases of CHB in Germany (2017–2030)

Table 18: Total Diagnosed Prevalent cases of CHB in Germany (2017–2030)

Table 19: Gender-specific Diagnosed Prevalent Cases of CHB in Germany (2017–2030)

Table 20: Age-specific Prevalent Cases of CHB in Germany (2017–2030)

Table 21: Diagnosed Prevalent Cases of CHB by Impact on Liver in Germany (2017–2030)

Table 22: Total Treated cases of CHB in Germany (2017–2030)

Table 23: Total Prevalent Cases of CHB in France (2017–2030)

Table 24: Total Diagnosed Prevalent cases of CHB in France (2017–2030)

Table 25: Gender-specific Diagnosed Prevalent Cases of CHB in France (2017–2030)

Table 26: Age-specific Prevalent Cases of CHB in France (2017–2030)

Table 27: Diagnosed Prevalent Cases of CHB by Impact on Liver in France (2017–2030)

Table 28: Total Treated cases of CHB in France (2017–2030)

Table 29: Total Prevalent Cases of CHB in Italy (2017–2030)

Table 30: Total Diagnosed Prevalent cases of CHB in Italy (2017–2030)

Table 31: Gender-specific Diagnosed Prevalent Cases of CHB in Italy (2017–2030)

Table 32: Age-specific Prevalent Cases of CHB in Italy (2017–2030)

Table 33: Diagnosed Prevalent Cases of CHB by Impact on Liver in Italy (2017–2030)

Table 34: Total Treated cases of CHB in Italy (2017–2030)

Table 35: Total Prevalent Cases of CHB in Spain (2017–2030)

Table 36: Total Diagnosed Prevalent cases of CHB in Spain (2017–2030)

Table 37: Gender-specific Diagnosed Prevalent Cases of CHB in Spain (2017–2030)

Table 38: Age-specific Prevalent Cases of CHB in Spain (2017–2030)

Table 39: Diagnosed Prevalent Cases of CHB by Impact on Liver in Spain (2017–2030)

Table 40: Total Treated cases of CHB in Spain (2017–2030)

Table 41: Total Prevalent Cases of CHB in the United Kingdom (2017–2030)

Table 42: Total Diagnosed Prevalent cases of CHB in the United Kingdom (2017–2030)

Table 43: Gender-specific Diagnosed Prevalent Cases of CHB in the United Kingdom (2017–2030)

Table 44: Age-specific Prevalent Cases of CHB in the United Kingdom (2017–2030)

Table 45: Diagnosed Prevalent Cases of CHB by Impact on Liver in the United Kingdom (2017–2030)

Table 46: Total Treated cases of CHB in the United Kingdom (2017–2030)

Table 47: Total Prevalent Cases of CHB in Japan (2017–2030)

Table 48: Total Diagnosed Prevalent cases of CHB in Japan (2017–2030)

Table 49: Gender-specific Diagnosed Prevalent Cases of CHB in Japan (2017–2030)

Table 50: Age-specific Prevalent Cases of CHB in Japan (2017–2030)

Table 51: Diagnosed Prevalent Cases of CHB by Impact on Liver in Japan (2017–2030)

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Progression of Hepatitis B infection

Figure 3: Acute Hepatitis B Infection

Figure 4: Chronic Hepatitis B Infection

Figure 5: Chronic Hepatitis B Infection by age

Figure 6: Signs and Symptoms of Hepatitis B Infection

Figure 7: Risk factors of Hepatitis B Infection

Figure 8: Transmission of Hepatitis B Virus

Figure 9: Steps in HBV replication

Figure 10: Serologic course of hepatitis B virus (HBV) infection.

Figure 11: Complications of Hepatitis B Infection

Figure 12: Hepatitis B Infection Profile

Figure 13: Transient Elastography using FibroScan

Figure 14: Total Prevalent Cases of CHB in the 7MM (2017–2030)

Figure 15: Total Diagnosed Prevalent cases of CHB in the 7MM (2017–2030)

Figure 16: Gender-specific Diagnosed Prevalent Cases of CHB in the 7MM (2017–2030)

Figure 17: Age-specific Diagnosed Prevalent Cases of CHB in the 7MM (2017–2030)

Figure 18: Diagnosed Prevalent Cases of CHB by Impact on Liver in the 7MM (2017–2030)

Figure 19: Treated cases of CHB in the 7MM (2017–2030)

Figure 20: Total Prevalent Cases of CHB in the United States (2017–2030)

Figure 21: Total Diagnosed Prevalent cases of CHB in the United States (2017–2030)

Figure 22: Gender-specific Diagnosed Prevalent Cases of CHB in the United States (2017–2030)

Figure 23: Age-specific Diagnosed Prevalent Cases of CHB in the United States (2017–2030)

Figure 24: Diagnosed Prevalent Cases of CHB by Impact on Liver in the United States (2017–2030)

Figure 25: Treated cases of CHB in the United States (2017–2030)

Figure 26: Total Prevalent Cases of CHB in Germany (2017–2030)

Figure 27: Total Diagnosed Prevalent cases of CHB in Germany (2017–2030)

Figure 28: Gender-specific Diagnosed Prevalent Cases of CHB in Germany (2017–2030)

Figure 29: Age-specific Diagnosed Prevalent Cases of CHB in Germany (2017–2030)

Figure 30: Diagnosed Prevalent Cases of CHB by Impact on Liver in Germany (2017–2030)

Figure 31: Treated cases of CHB in Germany (2017–2030)

Figure 32: Total Prevalent Cases of CHB in France (2017–2030)

Figure 33: Total Diagnosed Prevalent cases of CHB in France (2017–2030)

Figure 34: Gender-specific Diagnosed Prevalent Cases of CHB in France (2017–2030)

Figure 35: Age-specific Diagnosed Prevalent Cases of CHB in France (2017–2030)

Figure 36: Diagnosed Prevalent Cases of CHB by Impact on Liver in France (2017–2030)

Figure 37: Treated cases of CHB in France (2017–2030)

Figure 38: Total Prevalent Cases of CHB in Italy (2017–2030)

Figure 39: Total Diagnosed Prevalent cases of CHB in Italy (2017–2030)

Figure 40: Gender-specific Diagnosed Prevalent Cases of CHB in Italy (2017–2030)

Figure 41: Age-specific Diagnosed Prevalent Cases of CHB in Italy (2017–2030)

Figure 42: Diagnosed Prevalent Cases of CHB by Impact on Liver in Italy (2017–2030)

Figure 43: Treated cases of CHB in Italy (2017–2030)

Figure 44: Total Prevalent Cases of CHB in Spain (2017–2030)

Figure 45: Total Diagnosed Prevalent cases of CHB in Spain (2017–2030)

Figure 46: Gender-specific Diagnosed Prevalent Cases of CHB in Spain (2017–2030)

Figure 47: Age-specific Diagnosed Prevalent Cases of CHB in Spain (2017–2030)

Figure 48: Diagnosed Prevalent Cases of CHB by Impact on Liver in Spain (2017–2030)

Figure 49: Treated cases of CHB in Spain (2017–2030)

Figure 50: Total Prevalent Cases of CHB in the United Kingdom (2017–2030)

Figure 51: Total Diagnosed Prevalent cases of CHB in the United Kingdom (2017–2030)

Figure 52: Gender-specific Diagnosed Prevalent Cases of CHB in the United Kingdom (2017–2030)

Figure 53: Age-specific Diagnosed Prevalent Cases of CHB in the United Kingdom (2017–2030)

Figure 54: Diagnosed Prevalent Cases of CHB by Impact on Liver in the United Kingdom (2017–2030)

Figure 55: Treated cases of CHB in the United Kingdom (2017–2030)

Figure 56: Total Prevalent Cases of CHB in Japan (2017–2030)

Figure 57: Total Diagnosed Prevalent cases of CHB in Japan (2017–2030)

Figure 58: Gender-specific Diagnosed Prevalent Cases of CHB in Japan (2017–2030)

Figure 59: Age-specific Diagnosed Prevalent Cases of CHB in Japan (2017–2030)

Figure 60: Diagnosed Prevalent Cases of CHB by Impact on Liver in Japan (2017–2030)

Figure 61: Treated cases of CHB in Japan (2017–2030)

Figure 62: Hepatitis D:  coinfection and superinfection with Hepatitis B

Forward to Friend

Need A Quote